BeOne Medicines Ltd. Share Price

BeOne Medicines Ltd. Share Price

NASDAQ: ONC | Mega Cap
$371.36
-$1.99 (-0.53%) Last updated on 30 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

BeOne Medicines Ltd. Stock Performance

Open
$372.06
Prev. Close
$373.35
Circuit Range
N/A
Day Range
$368.94 - $376.11
Year Range
$253.96 - $388.50
Volume
25,615
Average Traded
$372.12

BeOne Medicines Ltd. Share Price Today

As of 30 October 2026, BeOne Medicines Ltd.'s share price is $371.36. The stock opened at $372.06, compared to its previous close of $373.35. During today's trading session, BeOne Medicines Ltd.'s share price traded between $368.94 and $376.11, with an average price of $372.53. Over the past 52 weeks, the stock has recorded a high of $388.50 and a low of $253.96. In terms of performance, BeOne Medicines Ltd.'s share price has risen by 25.84% over the last six months and is up 19.17% on a year-on-year basis.

BeOne Medicines Ltd. Share Price Chart

Line chart of the BeOne Medicines Ltd. price trend over the selected period. The price fell overall, ranging from 368.88 to 376.30, ending at 371.36.
$368.94$376.11
L
Show Current Price
H

BeOne Medicines Ltd. Stock Fundamentals & Key Indicators

Market Cap
$526.52B
PE Ratio (TTM)
64.41
Dividend Yield
0.00%
EPS (TTM)
$5.80
Revenue (TTM)
$5.34T
Return On Equity (TTM)
12.67%
Profit Margin
5.37%
Debt to Equity
0.21
Quarterly Earnings Growth YoY
89.85%

BeOne Medicines Ltd. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$1412.28$1498.17$1513.44$1705.07
Net Profit$124.84$66.50$227.36$237.01
Net Profit Margin8.84%4.44%15.02%13.90%
Income ChangeN/A-46.73%241.89%4.24%

BeOne Medicines Ltd. Annual Profit & Loss

All figures in USD

Particulars2025
Revenue$5343.03
Net Profit$286.93
Net Profit Margin5.37%
Income ChangeN/A

About BeOne Medicines Ltd.

Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.

BeOne Medicines Ltd. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$368.41
$371.56
+1.51%
Sep 2026
$351.40
$366.04
-1.76%
Aug 2026
$314.00
$372.58
+17.93%
Jul 2026
$285.00
$315.92
+10.80%
Jun 2026
$284.56
$285.13
-0.91%
May 2026
$293.89
$287.76
-2.49%
Apr 2026
$307.03
$295.10
-0.60%
Mar 2026
$305.50
$296.87
-6.27%
Feb 2026
$332.48
$316.75
-6.93%
Jan 2026
$308.04
$340.34
+12.03%
Dec 2025
$339.19
$303.81
-10.89%
Nov 2025
$313.97
$340.92
+9.40%

ONC Share Price FAQs